Latest news and articles about Chinese pharmaceuticals
Total: 1 articles found
ST Huluwa, a Chinese paediatric drug manufacturer, saw 23.9 million shares (about 5.97% of equity) sold at a judicial auction after a major-shareholder pledge triggered creditor action. Buyers included private funds and individuals; Huluwa Investment remains the largest shareholder but its stake fell to 35.79%. The sale highlights acute liquidity, governance and regulatory problems at the company and the broader risks that share pledges pose in China’s markets.
